Business Context and Reporting Period
This Form 8-K Current Report was filed by Corvus Pharmaceuticals, Inc. on January 28, 2019. The filing reports a change in the composition of the Board of Directors, specifically the election of a new director and the resignation of a former director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Resignation: Peter Moldt, Ph.D., resigned from the Board of Directors and from the Audit Committee and Nominating and Corporate Governance Committee effective January 28, 2019. The resignation is not due to any disagreement with the Company.
- Board Election: Linda S. Grais, M.D., J.D., was elected as a Class I director to replace Dr. Moldt. She was appointed to the Audit Committee and Nominating and Corporate Governance Committee.
- Term: Dr. Grais's term commences on January 28, 2019, and expires at the 2020 annual meeting of stockholders or until a successor is elected.
Compensation, Risks, and Unusual Items
Compensation Arrangements
- Retainer: Dr. Grais is entitled to a $35,000 annual retainer for Board service.
- Initial Equity Award: An option to purchase 30,000 shares of Common Stock was granted on the date of appointment. This award vests in three equal tranches (1/3) on each yearly anniversary of the appointment date, subject to continued service.
- Subsequent Awards: As a non-employee director, she is eligible for annual grants of 15,000 shares, which vest on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting.
- Change in Control: All equity awards held by non-employee directors vest in full immediately prior to a change in control.
- Exercise Price: Options are granted at 100% of the fair market value on the date of grant with a maximum term of ten years.
Indemnification
The Company will enter into a standard indemnification agreement with Dr. Grais, requiring the Company to indemnify her to the fullest extent permitted by Delaware law for expenses, judgments, penalties, and fines incurred in actions arising from her services as a director.
Risks and Contingencies
The filing states there are no arrangements or understandings between Dr. Grais and the Company regarding her appointment other than those disclosed. No transactions exceeding $120,000 involving Dr. Grais have occurred since the beginning of the last fiscal year.
Key Facts for Investor Verification
- Verify the independence and qualifications of the new director, Dr. Linda S. Grais, particularly regarding her roles on the Audit and Nominating committees.
- Confirm the impact of the equity grant (30,000 shares) on the company's outstanding share count and potential dilution.
- Review the full text of the Non-Employee Director Compensation Program and Indemnification Agreement referenced in the filing (Exhibits 10.12 and 10.6 to the Form S-1) for detailed terms.
- Monitor future filings for the 2020 annual meeting to confirm the election of Dr. Grais's successor or re-election.